Proactive Investors - Run By Investors For Investors

Sareum surges as it signals progress on pre-clinical programmes

"The potential for our two preclinical TYK2/JAK1 inhibitors in autoimmune diseases and cancer is gaining increasing clinical validation and we are convinced that SDC-1801 and SDC-1802 represent strong and well-differentiated candidates to address diseases within these areas," said Dr Tim Mitchell, the Sareum CEO.
Drug development
"We are focused on advancing these exciting preclinical candidates towards human trials as quickly as possible, aiming for first-in-man studies to begin in 2020."

Sareum Holdings PLC (LON:SAR), the specialist small molecule drug development business, has hailed the recent progress of its clinical and pre-clinical programmes.

Following last week’s announcement of preliminary efficacy data for SRA737, a cancer drug it helped to develop, the company provided the market with an update on other developments within its active pre-clinical portfolio.

READ Sareum Holdings hails early-stage efficacy data for cancer drug

Sareum's SDC-1801 and SDC-1802 drug candidates, which are respectively being developed to treat autoimmune diseases and cancers are progressing through pre-clinical development and should undergo first in-human clinical trials in 2020.

Both Sareum programmes have progressed well since being chosen in September 2018 for further development.

Data items arising from some of the development work are being prepared for submission to a peer-reviewed publication and a conference presentation, Sareum said.

Sareum's recent activities have focused on toxicology studies designed to gain insight into the maximum-tolerated doses of SDC-1801 and SDC-1802 in rodents.

SDC-1801, the autoimmune diseases candidate, is further advanced and currently demonstrating excellent tolerability with doses up to 30 times the level that gave good responses in efficacy studies; a maximum tolerated dose has yet to be reached.

In addition, the company has been exploring reliable manufacturing routes to produce each candidate for preclinical and clinical studies; such a route has been developed for SDC-1801 and activities continue to confirm a route of synthesis for SDC-1802.

"We believe there is a clear opportunity to generate significant value for our shareholders over the next 12 months, given recent progress with both our clinical and preclinical programmes,” said Dr Tim Mitchell, the chief executive officer of Sareum.

Shares in Sareum were up 4.8% in early deals.


View full SAR profile View Profile

Sareum Holdings PLC Timeline

Related Articles

A woman with severe depression
April 25 2019
The New York clinical-stage biopharmaceutical company has several drugs in the pipeline capable of generating hefty revenue
human kidneys
May 06 2019
The Danish company is seeking FDA approval of the test for use in both adults and children
copd radiograph
April 02 2019
City broker Peel Hunt reckons the recent approvals “support the top-line forecasts in our model that should see Circassia achieve EBITDA positivity in 2020”

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use